News for Co-Diagnostics, Inc. (CODX)

PR NewswireSALT LAKE CITY, July 15, 2025 SALT LAKE CITY, July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a

Co-Diagnostics (CODX) will host a booth at WHX Kuala Lumpur, a major healthcare exhibition in Southeast Asia, from July 16-18, 2025. The event is expect

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. ( CODX) (the ”œCompany” or ”œCo-Dx”), a molecular diagnostics company with a

Co-Diagnostics, Inc. (CODX) to participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference will fe

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Co-Diagnostics In

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCODX.OQ - Co-Diagnostics IncQ1 2025 Co-Diagnostics Inc Earnings CallMay 08, 2025 / 08:30PM GMT

CoDiagnostics (CODX) delivered earnings and revenue surprises of 27.27% and 86.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. ( CODX), a molecular diagnostics company with a unique, patented platform for the develo

Revenue: $0.1 million, significantly below the estimated $0.38 million, reflecting a decline from $0.5 million in Q1 2024 due to timing of grant revenue recogn

Co-Diagnostics (CODX) will release its first quarter 2025 earnings on May 8, 2025, after market close. A conference call and webcast will occur at 4:30 p.m.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

Total Revenue: $3.9 million for fiscal year 2024, down from $6.8 million in the prior year.Grant Revenue: $3.1 million in 2024.Product Revenue: $0.8 million in

Mar 27, 2025 / 08:30PM GMTOperator Good day, and welcome to the Co-Diagnostics fourth quarter and full year 2024 earnings conference call. (Operator Instruction

CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Explore Co-Diagnostics' Q4 2024 earnings insights, FDA resubmissions, TB & HPV test pipelines, and international market growth plans.

PR NewswireSALT LAKE CITY, March 27, 2025 SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

Revenue: $3.9 million for the full year 2024, falling short of the annual estimate of $4.14 million.Net Loss: $37.6 million, compared to a net loss of $35.3 mi

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

PR NewswireSALT LAKE CITY, March 3, 2025 The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV